8-K: TG Therapeutics Secures $250 Million Loan, Announces Share Buyback and Strong Briumvi Sales

TG Therapeutics has secured a $250 million loan facility, initiated a $100 million share repurchase program, and reported strong second-quarter sales of Briumvi, leading to increased full-year revenue guidance.

Summary

• TG Therapeutics secured a $250 million term loan facility with Blue Owl Capital and HealthCare Royalty, which will mature on August 2, 2029.
• The loan includes an uncommitted additional facility of up to $100 million.
• The company used the loan proceeds to repay existing debt of $107 million and plans to use up to $100 million for a share repurchase program.
• The interest rate on the loan is based on a margin plus either a base rate or Term SOFR, with the margin determined quarterly based on US Net Sales.
• The company reported second-quarter 2024 U.S. Briumvi net revenue of $72.6 million, a significant increase from $16.0 million in the same quarter of 2023.
• Full-year 2024 U.S. Briumvi net revenue target has been raised to approximately $290 $300 million, up from the previous guidance of $270 $290 million.
• The company achieved cash flow positive status for the second quarter of 2024.
• A share repurchase program of up to $100 million was authorized by the Board of Directors.
• The company identified an error related to the expense recognition of a restricted stock grant in 2021, which was deemed immaterial but resulted in a material weakness in internal control over financial reporting.
• The company will file an amended 10-K to address the material weakness.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong Briumvi sales, increased revenue guidance, a new credit facility, and a share repurchase program. However, the identification of a material weakness in internal control and the risks associated with commercialization temper the overall optimism.

Positives

• The new $250 million credit facility provides financial flexibility and allows for debt repayment and share buybacks.
• Briumvi sales are exceeding expectations, leading to increased revenue guidance.
• The company is now cash flow positive for the second quarter of 2024.
• The share repurchase program signals confidence in the company's future prospects.
• The initiation of a phase 1 trial for subcutaneous ublituximab and FDA clearance for azer-cel demonstrate progress in R&D.
• The company has secured a national contract with the Department of Veterans Affairs for Briumvi.
• The company has obtained three additional patents for Briumvi, extending patent protection through 2042.

Negatives

• The company identified a material weakness in its internal control over financial reporting related to a restricted stock grant.
• The company will need to file an amended 10-K to address the material weakness.
• The company has incurred significant selling, general and administrative expenses due to the Briumvi commercial launch.
• The company has experienced a decrease in R&D expenses during the three months ended June 30, 2024, primarily due to reduced clinical trial related expense and license milestones incurred during the period.

Risks

• The company's share repurchase program depends on various factors, including market conditions and alternative investment opportunities.
• The company's future results may differ materially from expectations due to changes in stock price, market conditions, and unexpected capital requirements.
• The remediation of the material weakness in internal control may not be completed in a timely manner.
• The company relies on third parties for manufacturing, distribution and supply of Briumvi.
• There are risks associated with the commercialization of Briumvi, including maintaining a commercial infrastructure, obtaining payor coverage, and sustaining HCP interest.
• The company faces potential regulatory challenges to its plans to seek marketing approval for Briumvi in jurisdictions outside of the U.S.

Future Outlook

The company anticipates that its cash, cash equivalents, and investment securities, combined with projected revenues from Briumvi, will be sufficient to fund its business based on its current operating plan. The company also plans to study Briumvi in an additional autoimmune disease outside of MS and commence a clinical trial evaluating azer-cel in autoimmune diseases, starting with progressive MS.

Management Comments

• Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, 'We are pleased to report another quarter of outperformance across all aspects of our business.'
• Mr. Weiss continued, 'We are also excited to announce our new $250 million credit facility with HealthCare Royalty and Blue Owl Capital that enables us to accelerate the initiation of a share repurchase program and pay down our current debt, while preserving our current cash to continue building our commercial infrastructure, ramping up our marketing efforts, and investing in our R&D programs.'

Industry Context

The announcement reflects a positive trend in the biotechnology sector, where companies are increasingly focusing on commercializing innovative therapies and managing their financial positions through strategic financing and share buyback programs. The strong sales of Briumvi and the expansion of its clinical applications align with the growing demand for effective treatments for autoimmune disorders like multiple sclerosis.

Comparison to Industry Standards

• The 350% year-over-year growth in Briumvi sales is significantly higher than the average growth rate for pharmaceutical products in the MS market, which typically ranges from 10-20% annually.
• The company's move to secure a $250 million loan facility is comparable to other biotech companies that seek to refinance debt and fund growth initiatives, such as Vertex Pharmaceuticals' recent debt offerings.
• The share repurchase program is a common strategy among mature biotech companies with strong cash flow, similar to Amgen's consistent share buyback programs.
• The initiation of a phase 1 trial for subcutaneous ublituximab is in line with industry trends towards more convenient drug delivery methods, similar to Roche's development of subcutaneous formulations for its MS therapies.
• The FDA clearance for azer-cel in progressive MS is a significant step, placing TG Therapeutics in competition with companies developing CAR-T therapies for autoimmune diseases, such as Novartis and Bristol Myers Squibb.

Corporate Governance

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the potential for increased stock value.
• Employees may experience increased job security due to the company's improved financial position.
• Patients will benefit from the continued availability of Briumvi and the development of new therapies.
• Creditors will be reassured by the company's improved financial stability and debt repayment.
• Suppliers will benefit from the company's continued operations and increased demand for Briumvi.

Next Steps

• The company will file an amended 10-K to address the material weakness in internal control over financial reporting.
• The company will continue to execute its share repurchase program.
• The company will continue to commercialize Briumvi in the U.S. and Europe.
• The company will study Briumvi in an additional autoimmune disease outside of MS.
• The company will commence a clinical trial evaluating azer-cel in autoimmune diseases, starting with progressive MS.
• The company will present additional data from the ENHANCE Phase 3b CD20 switch trial.

Key Dates

Keywords

Briumvi, ublituximab, multiple sclerosis, share repurchase, term loan, revenue guidance, clinical trial, azer-cel, financial results, material weakness